Clinical trial · Interventional
CART-19 Cells for R/R B-cell Lymphoma
CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma
NCT03391726CI-TRIAL-00031049CCFRRBLunknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory B-cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CART-19 cells | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- CART-19 cells treat
- interventionNames
- Other: CART-19 cells
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- Adverse events that are related to treatment
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent * Aged between 1-65 years * Patients with relapse/refractory B-cell lymphoma * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70% Exclusion Criteria: * Pregnant or lactating females. * Any co-morbidity precluding the administration of CART-19 cells.
References
Publications (0)
Data not yet available
No reference posted for this study.